fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Salbutamol

All products: general benefit

Apo-Salvent · DIN 02146843 · 2 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.Discontinued December 20, 2018 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Apo-Salvent · DIN 02146843 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-12-20 · brand APO-SALVENT TABLETS - 2MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG · company Kanzy medipharm inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Salvent: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1274). What the ministry pays, not the patient.

Ministry pays: $0.1274 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02146843)

Source record
DIN 02146843: Apo-Salvent Raw flags: sec3=Y Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.1274; ministry $0.1274 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02146843 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18068
Interchangeable products
Ventolin · DIN 01961039 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since December 20, 2018 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (R03C): coverage varies; not interchangeable

  • Orciprenaline (Alupent): general benefit, not a benefit
Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE 12:12 Sympathomimetic (Adrenergic) Agents

ORCIPRENALINE SULFATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2mg/mL · O/L

EPINEPHRINE HCL

· 1 products · General benefit · strengths: 30mg/30mL · Inj Sol-30mL Pk

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-SALBUTAMOL STERINEBSTM P.F. (salbutamol sulphate Solution) is indicated for: • the treatment of severe bronchospasm associated with exacerbations of chronic bronchitis and bronchial asthma. It can be used by “wet” nebulization. When administered through a nebulizer, it should be used with compressed air or oxygen. Pediatrics (< 5 years of age): Experience is insufficient for recommending the treatment of children under 5 years of age. https://pdf.hres.ca/dpd_pm/00084629.PDF PM date: October 28, 2022 Source product: TEVA-SALBUTAMOL STERINEBS P.F.; DIN 01926934; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.